Over the last five years, the healthcare industry has witnessed an explosive surge in digital health services, revolutionizing the way we access medical care. Patients today are taking charge of their health journey by using different digital tools to stay on top of their preventative screenings, implement dietary and lifestyle changes, access mental health resources, and so much more. In this conversation, patient advocates and industry leaders from Noom, Thrive, and Pfizer, dive into the potential power of artificial intelligence and the anticipated transformation in personalized health plans. They share real-world examples that highlight how digital technologies are helping patients feel empowered and shape the future of healthcare. 

While cancer deaths in the United States have declined in recent years, some populations are being left behind—facing complicated challenges to accessing the care they need. Intervening at the earliest stages of disease onset is critical to cancer treatment success and to reducing the risk of recurrence. So how do we create a world where all people with cancer are quickly diagnosed and can live better, longer lives as science advances? In this conversation, patient advocates and healthcare leaders from Pfizer, the American Cancer Society, and the Healthcare Businesswomen’s Association, discuss the power of collaboration in the effort to “Outdo Cancer.”

Podcasting has become essential for communicating breakthroughs in science, offering an accessible and engaging platform to reach diverse audiences. This evolving medium fosters deeper connections by delivering trusted information in accessible and compelling ways. In this conversation, audio makers from Pfizer, Acast, and TED, discuss what it takes to stand out in the science podcast space, insights on strategy, and how they're working to shape the future of health communication.

So far in this season, we’ve explored how innovations throughout history have brought us to where we are now. We talked about how drug discovery changed from a serendipity-based to data-based endeavor. Then, we explored the powerful hardware and smart software required to accommodate big data. Now, the door to the future of AI in drug discovery is open. In our final episode, we’re looking toward the future, to understand where today’s advancements could potentially take us.

With a trove of data and powerful hardware to process it, software is the last element of our artificial intelligence story. In this episode, host Jeremiah Owyang and expert guests explore the history of advancement behind the software that powers AI today. They delve into the creation of neural networks at the heart of this technology and how scientists are partnering with AI to revolutionize the complex process of drug development and discovery. 

Last episode discussed data and how crucial large swaths of data are in assisting drug development. But more data requires a lot of storage – and that’s where hardware comes in. To make use of big data and all its possibilities, scientists need new tools at their disposal. In this episode, host Jeremiah Owyang, alongside expert guests, traces the rise of large-scale computational resources used throughout the medical industry today.

The intersection of biology and technology is revolutionizing drug discovery. In this episode, host Jeremiah Owyang and expert guests explore the crucial role of data in advancing medical science, from the serendipitous discoveries of the past to the cutting-edge techniques of today. They delve into the history of drug development, the rise of "omics," and the innovative single-cell sequencing that is transforming our understanding of the human body for the benefit of drug discovery. Today, scientists are using vast amounts of data to fuel artificial intelligence models, in the quest for new and better medicines.

Artificial intelligence has the potential to help save millions of lives by accelerating the discovery and development of treatments for humanity’s toughest diseases. Those AI innovations come down to three key factors: data, hardware, and software. Science Will Win Season 4 takes listeners on a journey back in time to learn how each of these three elements got where it is today. Each episode features interviews with historians and cutting-edge researchers, framing these deep historical dives within modern advancements in medical technology. What challenges did science have to overcome to bring us where we are today, the midst of an AI revolution in medicine? Tune in to this new, four-part series, coming soon!

Throughout history, humans have coalesced around moonshot culture to achieve audacious goals—from eradicating smallpox, to sequencing the human genome, to landing a spacecraft on Mars. These feats of human ingenuity didn’t happen in a vacuum, they were born from intentional innovation, a “coalition of the willing,” and a vision to outdo yesterday. This fireside chat with Drew Panayiotou, Former CMO of Pfizer and Devon Still, ex-NFL player and founder of Still Strong Foundation, explores innovations in cancer, their personal experiences with family members needing healthcare treatment, and what it will take to achieve Pfizer's next big moonshot to outdo cancer and achieve its vision, a world where people with cancer live better and longer lives.

Podcasting has exploded in the last 5 years, with every celebrity, brand, and influencer investing in audio. It’s estimated that 144MM people in the U.S. listen to a podcast monthly. With scale and an ability to build audience connections, podcasts have become effective at communicating complex information in a digestible way–making them perfect for sharing science-based stories. Many have heard the term "gene therapy," but how many know what it means? How do you explain the science behind artificial intelligence or designing the Mars Rover? Audio allows us to do this, while enhancing the impact of science communications. Join the Pfizer Podcast team, NASA, UT Austin, and Wonder Media Network as they share their audio expertise and accessible approach to scientific storytelling.

In a live taping of the Science Will Win podcast, Host and Artificial Intelligence Expert Jeremiah Owyang speaks to cutting-edge healthcare leaders about the impact that AI is having on the future of cancer. Thirty years ago, the thought of a world without cancer was nothing more than a dream. Similarly, AI was considered a technology that had yet to become reality. Today, we are reimagining a future where the AI revolution will help change the trajectory of cancer as we know it.

Is it possible to live in a world without antibiotic resistant bacteria? For the final episode of this season, we’re looking ahead to the future and getting a glimpse of a potential world in which we stay one step ahead of AMR, and what is helping us get there. Host Jeremiah Owyang and expert guests will talk about the education, surveillance, and policy efforts needed for success in the fight against antibiotic resistant bacteria. And we’ll explore how artificial intelligence can empower us in those efforts — and enable more effective, accessible, and equitable healthcare.

Artificial intelligence has the power to transform the way researchers study bacteria and develop new treatments – and we’re already seeing the benefits in healthcare. In part three, host Jeremiah Owyang and expert guests shed light on how AI expedites and enhances analyses, revolutionizing the search for new antibiotics. The benefits of AI extend to analyzing bacterial DNA, uncovering vulnerabilities, and potentially predicting bacterial evolution. This innovative technology aids scientists in pinpointing the most promising antibiotic candidates from a sea of possibilities and helps to streamline drug development.

Artificial intelligence could be an essential tool in the fight against antibiotic resistant bacteria – and data is a key part of developing that tool. In part two of this four-part series, expert guests break down the mechanics behind artificial intelligence and machine learning. As host Jeremiah Owyang traces the evolution of these tools in healthcare, he highlights the crucial role of data for understanding the problem of antibiotic resistance.

Medicine’s struggle with antibiotic resistant bacteria is reaching a crisis point. In part one of this four-part series, host Jeremiah Owyang and expert guests delve into the world of antibiotics, exploring their history, the rise of antibiotic resistance, and the story of a patient whose life was forever changed by antibiotic-resistant bacteria. They break down the critical issues at stake and discuss the multifaceted solutions needed to combat this pressing crisis – including artificial intelligence.

Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!

In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?

Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.

Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!

In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?